Revolution Medicines, Inc.

Ginkgo Bioworks, Inc.

Lifemine Therapeutics, Inc.

Warp Drive Bio, Inc.

Brian Roger Bowman

Gregory Lawrence Verdine

Jay Paul Morgenstern

Mathew Edward Sowa

Keith Earl Robison

Dylan Talbot Stiles

Sharon Ann Townson

Uddhav Kumar Shigdel

Daniel C Gray

Joshua Alan Van Dyke Blodgett

Lucy Foulston

John Baxter Biggins

Joshua A V Blodgett

Neville J Anthony

Matthew James Nichols

Joshua AV Blodgett

Among other things, the present disclosure provides technologies for efficient and effective identification of ETaGs, for example, from fungi genomes. In some embodiments, provided technologies are particularly useful for identifying mammalian targets of biosynthetic products of fungi. In some embodiments, provided technologies are particularly useful for identifying and/or prioritizing human targets for drug development. In some embodiments, provided technologies are particularly useful for developing modulators for human targets based on biosynthetic products of fungi.

Human therapeutic targets and modulators thereof

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.

Compounds that participate in cooperative binding and uses thereof

The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.

Compositions and methods for the production of compounds

The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or &#x3b2;-lactam compounds) with such nucleic acids, vectors, and/or host cells.

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for ex ample through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.

The invention relates to macrocyclic compounds capable of modulating biological processes through binding to a presenter protein and a target protein. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiment, the compounds of the invention 're-program' the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein.

Growing community of inventors

New Rochelle, NY, United States of America

Brian Roger Bowman